Evaluation of cell-penetrating peptide delivery of antisense oligonucleotides for therapeutic efficacy in spinal muscular atrophy

Evaluation of cell-penetrating peptide delivery of antisense oligonucleotides for therapeutic efficacy in spinal muscular atrophy

Antisense oligonucleotides (ASOs) are a widely used form of gene therapy, which is translatable to multiple disorders. A major obstacle for ASO efficacy is its bioavailability for in vivo and in vitro studies. To overcome this challenge we use cell-penetrating peptides (CPPs) for systemic delivery o...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Hammond, S, Abendroth, F, Gait, M, Wood, M
Format:	Journal article
Język:	English
Wydane:	Springer 2019

Podobne zapisy

Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy
od: Shabanpoor, F, i wsp.
Wydane: (2017)

NOVEL CELL PENETRATING PEPTIDES FOR SKELETAL AND CARDIAC MUSCLE DELIVERY OF PMO ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
od: Hammond, S, i wsp.
Wydane: (2011)

Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape
od: Wood, M, i wsp.
Wydane: (2017)

Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy
od: Suzan M. Hammond, i wsp.
Wydane: (2022-12-01)

Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
od: Hammond, S, i wsp.
Wydane: (2016)

Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA
od: Järver, P, i wsp.
Wydane: (2012)

Assessment of Nuclear Gem Quantity for Evaluating the Efficacy of Antisense Oligonucleotides in Spinal Muscular Atrophy Cells
od: Haya Al-Hilal, i wsp.
Wydane: (2024-01-01)

Perfluoroaryl Bicyclic Cell-Penetrating Peptides for Delivery of Antisense Oligonucleotides
od: Wolfe, Justin, i wsp.
Wydane: (2020)

Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
od: Haiyan Zhou, i wsp.
Wydane: (2020-06-01)

LONG-TERM RELEASE DELIVERY METHOD OF ANTISENSE OLIGONUCLEOTIDES IN HIPSC DERIVED MOTONEURONS FROM SPINAL MUSCULAR ATROPHY DISEASE
od: Maria Victoria Martinez Dominguez, i wsp.
Wydane: (2023-10-01)

PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.
od: Hammond, S, i wsp.
Wydane: (2010)

Synergistic Effect of an Antisense Oligonucleotide and Small Molecule on Splicing Correction of the Spinal Muscular Atrophy Gene
od: Eric W Ottesen, i wsp.
Wydane: (2024-02-01)

Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients
od: Lars Hendrik Müschen, i wsp.
Wydane: (2021-02-01)

Optimizing tissue-specific antisense oligonucleotide-peptide conjugates.
od: Betts, C, i wsp.
Wydane: (2012)

Cell-penetrating peptides-based strategies for the delivery of splice redirecting antisense oligonucleotides.
od: Andaloussi, S, i wsp.
Wydane: (2011)

Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide
od: Umme Sabrina Haque, i wsp.
Wydane: (2023-10-01)

Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy.
od: Betts, C, i wsp.
Wydane: (2013)

Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.
od: Koo, T, i wsp.
Wydane: (2013)

High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed SMN2 Splicing in Patient Fibroblasts
od: Wijaya, Yogik Onky Silvana, i wsp.
Wydane: (2022)

Comment on: “Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy” by Zhou et al.
od: Tai‐Heng Chen
Wydane: (2020-10-01)

A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
od: Alessio Paris, i wsp.
Wydane: (2023-02-01)

Nonviral delivery systems for antisense oligonucleotide therapeutics
od: Si Huang, i wsp.
Wydane: (2022-09-01)

Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA
od: Jamie Leckie, i wsp.
Wydane: (2024-06-01)

In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
od: Wang, Q, i wsp.
Wydane: (2010)

Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
od: Gait, M, i wsp.
Wydane: (2018)

Cell-penetrating peptides to enhance delivery of Oligonucleotide-based therapeutics
od: McClorey, G, i wsp.
Wydane: (2018)

The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.
od: Haiyan Zhou, i wsp.
Wydane: (2020-10-01)

Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function.
od: Yin, H, i wsp.
Wydane: (2008)

Progress in the Treatment of Antisense Oligonucleotides in Duchenne Muscular Dystrophy
od: XU Tingting, i wsp.
Wydane: (2022-04-01)

PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation.
od: Ezzat, K, i wsp.
Wydane: (2011)

Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review
od: Zorica Nakevska, i wsp.
Wydane: (2023-06-01)

Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse.
od: Yin, H, i wsp.
Wydane: (2010)

Peptide-mediated delivery of antisense oligonucleotides and chemotherapeutics across biological barriers
od: Fadzen, Colin MacLaine
Wydane: (2018)

Use of cell-penetrating-peptides in oligonucleotide splice switching therapy.
od: El Andaloussi, SA, i wsp.
Wydane: (2012)

Casimersen (AMONDYS 45™): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy
od: Milyard Assefa, i wsp.
Wydane: (2024-04-01)

Therapeutic strategies for spinal muscular atrophy: SMN and beyond
od: Bowerman, M, i wsp.
Wydane: (2017)

Therapeutic strategies for spinal muscular atrophy: SMN and beyond
od: Bowerman, M, i wsp.
Wydane: (2017)

Transport Oligonucleotides—A Novel System for Intracellular Delivery of Antisense Therapeutics
od: Oleg V. Markov, i wsp.
Wydane: (2020-08-01)

Machine Learning To Predict Cell-Penetrating Peptides for Antisense Delivery
od: Yao, Monica, i wsp.
Wydane: (2018)

Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy
od: Aoki, Y, i wsp.
Wydane: (2011)